Short answer
Vaxcyte, Inc. (PCVX) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$321M
- −127.8% YoY
- EPS (diluted)
- −$2.30
- −121.2% YoY
Source: XBRL data from the Vaxcyte, Inc. (PCVX) Q1 2026 10-Q on SEC EDGAR. USD.
Vaxcyte, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, no product sales; no YoY comparison disclosed
- Net loss $320.6M for Q1 2026; accumulated deficit $2.5B
- Cash, equivalents and investments $2.7B at March 31, 2026
- Public offering generated $632.5M gross proceeds from 12.65M shares at $50.00
- VAX-31 outlook: OPUS-1 topline data expected Q4 2026; OPUS-2 and OPUS-3 data expected first half 2027
Risk Factors
- Newly triggered regulatory risk: FDA non-inferiority threshold for VAX-31 adult Phase 3 set at 0.667
- Most material update: VAX-31 adult Phase 3 CMC strategy may face FDA challenges, causing delays or unanticipated costs
- Manufacturing risk: Prior VAX-24 process issues delayed Lonza drug-substance production through scheduling conflicts and capacity constraints
- Financial risk: $2.7 billion in cash, cash equivalents and investments expected to fund operations for at least 12 months
- Development concentration risk: Business success depends heavily on VAX-31, VAX-24 and future PCV candidates reaching approval and commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vaxcyte, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.